Wedbush Reiterates Neutral on Ultragenyx Pharmaceutical, Maintains $48 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico has reiterated a Neutral rating on Ultragenyx Pharmaceutical (NASDAQ:RARE), with a maintained price target of $48. This reaffirmation of the Neutral stance and price target suggests that Wedbush views the current valuation of RARE as fair, implying no significant short-term price movement is expected.
April 16, 2024 | 2:20 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Wedbush analyst Laura Chico reiterates a Neutral rating on Ultragenyx Pharmaceutical, with a maintained price target of $48, indicating a belief in the stock's current fair valuation.
The reiteration of a Neutral rating and maintenance of the price target by a reputable analyst suggests that there are no immediate catalysts expected to significantly move the stock price in the short term. This analysis is based on the assumption that the analyst's views are well-regarded and have the potential to influence market sentiment towards the stock.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 90